

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Eurolife Brands Inc. (the “Issuer” or “Eurolife”).

Trading Symbol: EURO

Number of Outstanding Listed Securities: 349,248,444

Date: September 3, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

See Item 2 below for a complete overview and discussion of the Issuer’s activities for the month of August 2019.

2. Provide a general overview and discussion of the activities of management.

On August 1, 2019, the Issuer announced that it intends to position the organization, rebranded as “Eurolife Brands Inc.” (EuroLife), as a global leader in providing international markets with responsible and evidence-based cannabis education, consumer packaged goods (“CPG”) brands, and consumer analytics powered by its Canvas.Me and Canvas Data platforms.

The Issuer recently announced it would be rebranding the Issuer to Eurolife Brands to better reflect the direction of the Issuer’s business activities. The Issuer has additionally secured the trading symbol “EURO” on the CSE, a move its strategic advisors see as strengthening the Issuer’s position in the capital markets by offering investors a clearer idea of its core focus. EuroLife will bring cannabis education, analytics and some of the world’s most popular brands to international markets and emerging regions around the world while researching and executing on strategic M&A opportunities with like-minded organizations in Europe, South America and beyond.

As part of its initial plans to grow EuroLife Brands, the Issuer recently announced it has obtained the exclusive licensing rights for the marketing, development and distribution of True Focus’ product suite and proprietary intellectual property portfolio across South America and in select

markets throughout Europe for a period of 10 years. True Focus' all natural, nutraceutical formulations are delivered via an oral spray treatment and are aimed at mitigating the effects of THC overconsumption. EuroLife aims to leverage its industry-leading analytics focused on pre-transactional consumer behaviour patterns to expand the True Focus brand across Europe and South America, where it has already set up a physical location in Medellin, Colombia, for its EuroLife South American headquarters.

EuroLife anticipates aggressive expansion and a wide range of product SKU's to be included in its initial product offering within short order, as it continues high-level engagements with strategic partners across North America, South America and Europe. The Issuer's focus is the result of months of judicious research and meticulous planning through various partners and close contacts on the ground in countries such as Germany, UK, United States and Colombia. EuroLife hopes to centralize the sale of European brands in the CBD CPG space, supported by education and analytics from its North American platforms - Cannabis.Me, Cannabis.Pet and Cannabis Data, specifically - which remain intrinsically linked to EuroLife's overall growth plans.

In support of EuroLife's ongoing mandate to enact strategic and value added M&A initiatives it has engaged several high-level strategic advisors with proven track records in capital markets and corporate finance, having raised hundreds of millions of dollars in addition to building enterprises with values in excess of \$250,000,000.

More information can be found at the Issuer's new website: www.EuroLifeBrands.com, and stay tuned for more exciting developments from the EuroLife and Cannabis team.

On August 13, 2019, the Issuer announced that further to its news release of July 31, 2019, it has completed its name change from "Cannvas MedTech Inc." to "EuroLife Brands Inc." to better reflect the direction of the Issuer's business.

The Issuer's trading symbol on the Canadian Securities Exchange (the "CSE") has changed to "EURO" and, on the OTC Pink Sheets (the "OTCPK"), remain "CANVF" until the pending symbol change has been approved. The trading symbol will remain as "3CM" on the Frankfurt Stock Exchange. The Issuer's new CUSIP number for its common shares is 29876F106 and ISIN is CA29876F1062.

The Issuer has been advised by the CSE that the common shares will commence trading under the new name, effective at the opening of trading on August 14, 2019. In the coming days, all the Issuer's digital properties will be updated to reflect new EuroLife branding.

The Issuer is also pleased to announce that, following the name change, the Issuer will have completed a subdivision (the "Stock Split") of its issued and outstanding common shares on the basis of four (4) to one (1). For greater clarity, shareholders of record as at August 15, 2019 (the "Record Date") will receive three (3) additional common shares for every one (1) common share held. In accordance with the Issuer's Articles, shareholder approval was not required for the Stock Split.

The Issuer's common shares commenced trading on a split-adjusted basis on August 14, 2019.

On August 21, 2019, the Issuer announced that its corporate rebranding and repositioning within the cannabis industry has been completed with the launch of its EuroLifeBrands.com company website and corporate refocus.

Demonstrating the Issuer's commitment to providing accessible cannabis education, its Director of Strategy and Education Daniel Davidzon was recently published in the National Post arguing for the crucial need for evidence-based cannabis education for cannabis consumers across Canada and the world. With so many cannabis-curious consumers confused over what treatments, products and services available to them, the need for an education-driven marketplace has grown exponentially and EuroLife is poised to lead the market with its repository of over 400 physician-backed and educator-approved articles and over 70 courses in its education platform.

The EuroLife executive team devoted a significant amount of time over the last quarter quantifying strategic partners across Europe in both the cannabis sector and other industries to determine the organization's realignment and strengthen the brand's presence across the continent. A recent report from the Brightfield Group, a leading market intelligence firm for the legal CBD and cannabis industries, estimated the European CBD market at USD \$318 million in 2018, with the expectation of booming growth over 400 percent through 2023. The global CBD market is projected to grow from USD \$1 billion in 2018 to USD \$16 billion by 2026, according to Fior Market Research, a futuristic market intelligence company

While the Issuer shifts its European and South American activities toward the CBD market, the anchor of its North American operations remains its Canadian and U.S.-focused digital cannabis education resource Cannabis.Me and Cannabis.Pet.

EuroLife is also pleased to announce the formation of a new Veterinary Advisory Board to guide educational content for its Cannabis.Pet platform, as well as two new culinary-focused appointments to its Cannabis Sciences Advisory Board.

Award-winning veterinarian Dr. Scott Bainbridge has been appointed as the Veterinary Advisory Board lead, bringing with him nearly 20 years of veterinary expertise across a range of practices. Dr. Bainbridge and his team of eight vets diagnose approximately 15,000 cases every year at his Dundas West Animal Hospital (DWAH) in Toronto. Recently honoured by the Ontario Veterinary Medical Association with a lifetime achievement for public service, Dr. Bainbridge makes regular appearances on radio and television, appearing on CP24's *Animal House Calls* as a regular contributor and acts as the expert veterinarian for Canadian Living Magazine.

Award-winning author and culinary herbalist Pat Crocker, and founder of Upward Cannabis Kitchen, Carlton Bone, join the Cannabis Sciences Advisory Board to provide insights into evidence-based education around cannabis-infused edibles and beverages while contributing potential consumer packaged goods offerings to the EuroLife Marketplace platform.

A prolific author and in-demand speaker, Pat Crocker has written over 22 cookbooks. Her latest project is *Healing Cannabis Edibles*, a revolutionary cookbook and healing guide encouraging informed decisions around cannabis consumption to potentially improve certain health conditions. Ms. Crocker's books have sold hundreds of thousands of copies and have been featured on bestseller's lists across North America, including The Globe and Mail.

The founder of Portland, Oregon-based Upward Cannabis Kitchen, Carlton Bone has a passion for crafting high quality cannabis products and has developed a tea-based cannabis beverage line. Carlton also acts as the Chief Information Officer for Dr. Melanie Bone, a physician and educator with a focus on the intersection of cannabis and women's health care. Recently, the two collaborated on creating cannabis-infused suppositories to support anyone who needs relief due to chronic pain or additional comfort during their cycle.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

N/A.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	261,000 (pre-split)	Exercise of options at \$0.30 (pre-split) per share.	General working capital.
Common Shares	261,936,333	Issuance of common shares pursuant to subdivision of issued and outstanding share capitalization on a 4:1 basis.	N/A

15. Provide details of any loans to or by Related Persons.

N/A.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Changes in commodity prices, in particular metal prices, and changes in the share performance of other junior mineral exploration companies may affect the Issuer's ability to raise financing.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **September 3, 2019**_____.

Shawn Moniz
Name of Director or Senior Officer

"Shawn Moniz"
Signature

CEO & Director
Official Capacity

<i>Issuer Details</i> Name of Issuer	For Month End	Date of Report YY/MM/D
Eurolife Brands Inc.	August 2019	19/09/03
Issuer Address 201-213 Sterling Road		
City/Province/Postal Code Toronto, ON M6R 2B2	Issuer Fax No. 800.489.0116	Issuer Telephone No. 800.489.0116
Contact Name Shawn Moniz	Contact Position CEO & Director	Contact Telephone No. 800.489.0116
Contact Email Address info@eurolifebrands.com	Web Site Address https://eurolifebrands.com/	